Compare Visa Inc (V) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Visa Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Visa Inc trades at $356.2 (market cap $685.71B), while Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B). The key difference: Visa Inc is far larger — about 5.6× Vertex Pharmaceuticals Incorporated's market cap, and Visa Inc pays a 0.74% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| V | VRTX | |
|---|---|---|
Market Cap | $685.71B | $121.95B |
Volume | 10,431,336 | — |
Sector | Financials | Health |
52-Week High | $365.14 | $529.59 |
52-Week Low | $295.52 | $366.54 |
Enterprise Value | $696.30B | $116.69B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $355.82, down 0.76% on the day, with a bullish technical outlook supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue growth remains robust, reaching $40B in 2025, and profitability is high with a net income margin of 51.68%. Recent news highlights Visa's focus on AI-driven commerce and stablecoin partnerships, positioning it for future payment innovations.
The stock offers a compelling long-term investment case with 85% analyst buy ratings and a $396.70 consensus price target, implying 11% upside. Key risks include competitive threats from fintech and regulatory pressures. Visa's strong cash flow and dividend payments provide shareholder value, but investors should monitor execution on AI initiatives and macroeconomic impacts on consumer spending.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
